Refractory Acute Lymphoblastic Leukemia Clinical Trials
2 recruiting trials for Refractory Acute Lymphoblastic Leukemia. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Refractory Acute Lymphoblastic Leukemia clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 2: 1, Phase 1 / Phase 2: 1.
Research is led by M.D. Anderson Cancer Center (1), Beijing GoBroad Hospital (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Bortezomib (drug, 1 trial), followed by Clofarabine, Cyclophosphamide.
Track Refractory Acute Lymphoblastic Leukemia trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic...
This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt...
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for...
This is a multi-center, open-label, non-randomized, phase 1/2 study of anti-CD5 CAR-T cell therapy in patients with CD5+ relapsed or refractory T-cell malignancies. A bayesian...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Refractory Acute Lymphoblastic Leukemia, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Refractory Acute Lymphoblastic Leukemia, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Refractory Acute Lymphoblastic Leukemia, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.